View Older Stories View More Recent Stories
-
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
-
Cosmos Health (COSM) CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200K
-
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
-
Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price
-
Cosmos Health (COSM) Integrates Bitcoin and Ethereum as Treasury Reserve Assets
-
Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
-
Cosmos Health (COSM) Reports Q3 Results
-
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
-
Cosmos Health Issues Letter to Shareholders
-
Cosmos Health (COSM) Issues Letter to Shareholders
-
Cosmos Health's (COSM) CosmoFarm Achieves Record Revenue
-
Cosmos Health’s Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
-
Cosmos Health (COSM) Files for 9.75M Share Offering by Selling Stockholders
-
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
-
Cosmos Health (COSM) Receives $500K+ in Orders for C-Scrub in the UK
-
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
-
Cosmos Health (COSM) Expands Global Presence into India
-
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
-
Cosmos Health (COSM) Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders
-
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
-
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
-
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
-
Cosmos Health (COSM) Secures Exclusivity Agreement with Virax Biolabs (VRAX) to Distribute mpox PCR Kits across the GCC
-
Virax Biolabs Group (VRAX) Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.
-
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
-
Cosmos Health (COSM) Regains Full Compliance with Nasdaq Listing Requirements
-
Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements
-
Cosmos Health's (COSM) Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE
-
Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE
-
Cosmos Health (COSM) Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
-
Cosmos Health Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
-
Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023
-
Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit
-
Cosmos Health (COSM) Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash
-
Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
-
Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share
-
Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar
-
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
-
Cosmos Health (COSM) Signs Distribution Agreement with ProMed Trading
-
Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity
-
Cosmos Health (COSM) Updates on Contract Manufacturing Division
-
Cosmos Health (COSM) Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Cosmos Health's (COSM) Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals
-
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
-
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule
-
Cosmos Health (COSM) Advances Commercialization of CCX0722 Weight Management Solution
-
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
-
Cosmos Health's (COSM) Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually
-
Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually
-
Cosmos Health (COSM) Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months
